Ember Therapeutics Inc.
Augmenting brown fat to combat metabolic diseases
This article was originally published in Start Up
The sole investor in a $34 million Series A financing, Third Rock hopes that Ember Therapeutics can be a pioneer in the relatively new field of using brown fat biology to fight metabolic disease. The start-up also has a program in insulin sensitivity, an approach to treating diabetes that has seen the launch of several drugs in the thiazolidinedione class, most of them compromised by major safety concerns.
You may also be interested in...
In an open letter to the European Commission, Parliament and Council presidents, more than 400 cosmetics companies and animal-rights groups accuse the European Chemicals Agency of effectively “shredding” the animal testing ban on cosmetics by requiring testing for certain chemicals under REACH.
Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.